Over the last couple of weeks, we have seen business development activities in the RNAi space that made me realize that the modality has fir...

Today, PTC Therapeutics reported full results from a 52-week trial with PTC518 for Huntington’s Disease.  The data failed to support an int...

Benitec announced today that almost 1 ½ years after filing an IND for its DNA-directed RNAi HCV candidate, it has now obtained liver biop...

Finally!   Long overdue (because so obvious and compelling), with the founding of Voyager Therapeutics, the foundations have now been laid...

A somewhat vexing problem with DNA-directed RNAi (ddRNAi) has been the heterogeneous mixture of small RNAs generated from a typical expre...

I just got notice of the September issuances of two additional US patents (US 8258285 and US 8263569) belonging to the Baulcombe IP es...

After years of pouring millions, if not billions into RNAi-related intellectual property (IP) and the development of double-strand RNA ...

I’ve been reminded a number of times by the staunch Benitec-supporters here that Texas-based biotech company Gradalis has been moving a ddRN...

With the backing of a $20M grant from the California Institute of Regenerative Medicines (CIRM), Calimmune has made progress in advancing a ...

My four years as a post-doc here in Stanford, during which my advisor Mark Kay served a term as the President of the American Society for Ge...

170 million people worldwide are infected with the Hepatitis C virus. Hep C, an RNA virus, is emerging as a significant public health probl...

I apologise for having been somewhat quiet recently on the blog. It is not that I lost my belief in RNAi Therapeutics, quite the opposite a...

Today, privately held Nucleonics announced it has received permission from the FDA to start phase I clinical trials using RNAi for the treat...